• TG Therapeutics recently reported positive topline Phase 1 data showing its subcutaneous BRIUMVI achieved at least equivalent exposure to the approved IV regimen and meaningful symptom improvements in acetylcholine receptor–positive myasthenia gravis patients, while generally maintaining a safety profile consistent with IV use in multiple sclerosis.
• The company also began a Phase 2 trial testing BRIUMVI as a maintenance therapy after efgartigimod induction in myasthenia gravis, highlighting its efforts to broaden BRIUMVI’s use beyond multiple sclerosis and potentially shift treatment patterns toward longer-acting B‑cell–targeted regimens.
• We’ll now examine how the move into myasthenia gravis with subcutaneous BRIUMVI could reshape TG Therapeutics’ previously MS‑centric investment narrative.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

TG Therapeutics Investment Narrative Recap

To own TG Therapeutics, you need to believe BRIUMVI can sustain and expand its role in B cell–mediated diseases while the company gradually diversifies beyond multiple sclerosis. The myasthenia gravis move with subcutaneous BRIUMVI adds an early but potentially meaningful new use case; however, the key near term catalyst still sits in MS with the subcutaneous and single‑infusion programs, and the biggest current risk remains TG’s dependence on BRIUMVI amid intense anti‑CD20 competition and payer pressure.

Against that backdrop, the most relevant recent announcement is the completion of enrollment and positive topline data from the ENHANCE Phase 3 trial of a single‑day 600 mg IV BRIUMVI infusion in MS, which showed bioequivalence to the original split‑dose regimen with no new safety signals. If regulators accept this regimen, it could meaningfully reinforce BRIUMVI’s convenience edge just as the myasthenia gravis program starts to take shape.

Yet beneath this progress, investors should also be aware of the growing pressure from government discounts and payer preference for lower cost at home therapies that could...

TG Therapeutics' narrative projects $1.5 billion revenue and $461.7 million earnings by 2029.

Uncover how TG Therapeutics' forecasts yield a $44.43 fair value, a 17% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling TG Therapeutics to reach about US$2.0 billion in revenue and roughly US$634.3 million in earnings by 2029, so if you lean toward that view you are effectively assuming faster subcutaneous BRIUMVI uptake and broader autoimmune success than the baseline story, while this new myasthenia gravis data could either support or challenge those expectations as the picture evolves.

Explore 7 other fair value estimates on TG Therapeutics - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your TG Therapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free TG Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate TG Therapeutics' overall financial health at a glance.

No Opportunity In TG Therapeutics?

Our top stock finds are flying under the radar-for now. Get in early:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.